Genera Research Ltd.

What Genera Research Ltd. does

Genera Research Ltd. is a privately held, clinical-stage biotechnology company headquartered in Sveta Nedelja, Croatia, developing recombinant human Bone Morphogenetic Protein 6 (rhBMP6) based biological drugs for bone regeneration. The company's core platform, OSTEOGROW, combines recombinant human BMP-6 with an autologous blood coagulum carrier to transform a patient's own peripheral blood into a personalized bone graft substitute, eliminating the need for autologous bone graft harvesting. The product family includes OSTEOGROW (general bone healing), OSTEOproSPINE (spinal fusion via PLIF/TLIF with OSTEOGROW-A and OSTEOGROW-B formulations), OSTEOforUNION / OSTEOGROW-C (bone fracture non-unions using a compression-resistant tricalcium phosphate matrix), and OSTEOproDENT (alveolar ridge augmentation in dental applications). Over 30 globally protected patents support the technology through 2043 across the US, EU, Canada, Australia, China, Japan, and India.

The company is currently pre-revenue and has been funded almost exclusively through non-dilutive European Union grants — €5.68M under FP7 (2012–2016), €5.05M through CERRM (2017–2022), €6.00M under Horizon 2020 OSTEOproSPINE (2018–2023), €2.5M under the Horizon Europe EIC Accelerator for OSTEOforUNION (2025–2026), and €2.7M in EU co-financing for OSTEOproDENT (2025–2028). Its go-to-market motion is enterprise-field-sales oriented toward hospitals, orthopaedic surgery centers, and spinal surgery departments globally, with commercialization planned via pharmaceutical distribution partnerships (discussions ongoing with US-based pharma and orthopaedic partners per BIO 2025 reporting). OSTEOproSPINE-B Phase II (n=143) and OSTEOGROW Phase I/II have shown promising safety and efficacy; OSTEOGROW-C is now in Phase III (TRL 8) with planned EU market entry in 2028 and US regulatory submission to follow.

Target customer segments are orthopaedic and spinal surgery (primary) plus dental/oral surgery, addressing large unmet needs: approximately 6 million global and 120,000 US annual fracture non-union cases, plus spinal fusion and dental implant bone regeneration indications. The company's leadership team — Prof. Slobodan Vukičević (CEO/CMO), Dora Adanić (COO/CFO), Hermann Oppermann (CTO, 110+ patents, ex-Genentech/Stryker Biotech), Kuber Sampath (CSO, 120+ patents), Mihaela Perić (CCO), Tamara Božić (Quality Chief), and Roland Zonai (CBO/BD) — combines decades of BMP biology, GMP manufacturing, and regulatory expertise. Operational partnerships with Cleveland Clinic Foundation, University of Zagreb School of Medicine, Sartorius Croatia, and the CERRM consortium underpin clinical execution and translational research.

Name

Genera Research Ltd.

Legal name

Genera Research Ltd.

Website

https://genera-research.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Genera Research Ltd. is a clinical-stage Croatian biotechnology company developing recombinant human Bone Morphogenetic Protein 6 (rhBMP6) biological drugs for bone regeneration, targeting orthopaedic, spinal, and dental surgery patients via its OSTEOGROW, OSTEOproSPINE, OSTEOforUNION, and OSTEOproDENT product families, with Phase III trials underway.

Ownership category

akta.pro rank

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Dental Equipment & Supplies (3843)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

akta.pro secondary industries

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB), Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Bone Grafting & Ridge Augmentation (GBR/Sinus Lift) (HLABACAG), Dental Implant Surgery & Bone Grafting (HLABAEAB)

Keywords

• Bone regeneration therapeutics
• Recombinant protein drugs
• Orthopaedic biologics
• Regenerative medicine
• Spinal fusion biologics

Headquarters

HQ city

Sveta Nedelja

HQ country

Croatia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Expected to generate revenue through commercialization of OSTEOGROW family of products (OSTEOGROW, OSTEOGROW-C, OSTEOproSPINE) upon regulatory approval. Target markets include EU and US for treatment of bone fracture non-unions, spinal fusion, and dental bone regeneration applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Genera Research Ltd. is a clinical-stage biotechnology company developing and manufacturing recombinant human Bone Morphogenetic Protein 6 (rhBMP6) based biological drugs for bone regeneration. Its core OSTEOGROW product combines recombinant human BMP-6 with the patient's own blood as a carrier to create a personalized bone graft substitute, eliminating the need for autologous bone harvesting. The portfolio includes OSTEOGROW for general bone regeneration, OSTEOproSPINE for spinal fusion, and OSTEOforUNION / OSTEOGROW-C (with compression resistant matrix) for bone fracture non-unions, supported by an OSTEOproDENT formulation for dental applications.

Product overview

Genera Research Ltd. is a clinical-stage biotechnology company developing a family of biological products based on recombinant human Bone Morphogenetic Protein 6 (rhBMP6) for bone regeneration. The core product OSTEOGROW uses the patient's own blood as a carrier to deliver rhBMP6, transforming blood into bone for orthopaedic, spinal, and dental applications. OSTEOproSPINE provides spinal fusion formulations (OSTEOGROW-A and OSTEOGROW-B), while OSTEOforUNION targets fracture nonunions with an enhanced ceramic matrix formulation. All products share the same rhBMP6 active ingredient but differ in delivery formulation and clinical application.

Differentiator

Problem solved

Functional benefit

Brands

• OSTEOGROW: Family of biological products for bone healing based on recombinant human BMP6 (rhBMP6) delivered in autologous blood coagulum carrier. Used for bone regeneration and treatment of orthopedic conditions.
• OSTEOproSPINE
• OSTEOforUNION
• OSTEOproDENT

Quantifiable outcome

• Phase I/II clinical trials completed with good safety profile - no serious adverse reactions reported
• +3 more outcomes

Named customers3 records

Segments4 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• Cleveland Clinic FoundationcoreStrategic or Co-development Partner · 1 November 2025Visited by Genera Research in November 2025 to present OSTEOGROW-C to Department of Orthopaedics and Traumatology and Innovation Department. Discussions focused on Cleveland Clinic's potential participation in Phase III clinical trial and defining future collaboration models.
• Sartorius Croatia – Libra Elektronik d.o.o.coreStrategic or Co-development Partner · 13 January 2025Lead partner in OSTEOproDENT project for development of advanced formulation for alveolar ridge augmentation. Project budget €4.67 million with €2.7 million EU co-financing (January 2025 - January 2028). Organized BioPharma & LabXperience 2026 conference where Genera Research participated as speaker and panelist.
• University of Zagreb School of MedicinecoreStrategic or Co-development Partner · 13 January 2025Partner in OSTEOproDENT project and CERRM (Center of Excellence for Reproductive and Regenerative Medicine). Clinical trial site for alveolar ridge regeneration study. Collaborates on GLP and GMP production of recombinant proteins.
• Dental Office BekavaccoreStrategic or Co-development Partner · 13 January 2025Clinical site partner in OSTEOproDENT project for testing Osteogrow in alveolar ridge regeneration following tooth extraction.
• CERRM - Center of Excellence for Reproductive and Regenerative Medicine ConsortiumcoreStrategic or Co-development Partner · 1 January 2017Genera Research is one of nine partner institutions in the Research Unit for Regenerative Medicine. Project funding €5,050,357.52. Integrates research groups from basic science, clinics, education and industry for translational research in regenerative medicine.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Bioventus: Bioventus offers a portfolio of orthobiologic bone graft substitutes and regenerative medicine products for orthopaedic and spine surgery. It is a direct peer to Genera Research in the bone regeneration and graft substitute space.
• Orthofix: Orthofix develops spine and orthopaedic biologics including bone graft substitutes for spinal fusion and fracture healing. Its regenerative medicine portfolio overlaps directly with Genera Research's OSTEOGROW-C and OSTEOproSPINE indications.
• MTF Biologics: MTF Biologics provides allograft-based bone graft substitutes and regenerative tissue products for orthopaedic, spinal, and dental applications. It is a direct peer in the bone graft substitute category across the same indications Genera Research targets.
• SeaSpine: SeaSpine (now part of Globus Medical) is a spine-focused company offering orthobiologic bone graft substitutes for spinal fusion procedures. It directly competes in the spinal fusion biologics segment targeted by OSTEOproSPINE.
• Cerapedics: Cerapedics develops peptide-based bone regeneration products (iP-Factor) for spinal fusion and orthopaedic applications. It is a direct peer in the biological bone graft substitute space targeting the same spinal and orthopaedic surgical call points.
• Xtant Medical: Xtant Medical is a specialty orthobiologics company offering bone graft substitutes and regenerative products for spinal and orthopaedic surgery. It directly competes in the bone graft substitute market Genera Research targets.

Broad incumbents

• DePuy Synthes (Johnson & Johnson): DePuy Synthes, J&J's orthopaedic franchise, offers bone graft substitutes and trauma/spine products. As a broad incumbent in orthopaedic surgery, it competes with Genera Research for surgeon adoption in fracture repair and spinal applications.
• Zimmer Biomet: Zimmer Biomet is a major orthopaedic devices and biologics company with bone graft and regenerative medicine offerings. It operates in the same orthopaedic and spinal surgery markets and competes for surgeon adoption.
• Medtronic: Medtronic markets INFUSE Bone Graft, the dominant recombinant human BMP-2 product for spinal fusion and orthopaedic bone regeneration. As the established incumbent in the BMP-based bone graft category, it is the most direct standard-of-care competitor OSTEOGROW-C must displace.
• Stryker: Stryker has historical involvement in BMP-based orthobiologics via Stryker Biotech (where Genera's CTO Dr. Oppermann previously worked). As a large orthopaedic devices incumbent, it is both a comparable organization and a potential commercialization partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/genres

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genera Research Ltd.